From the Department of Psychiatry and Behavioral Sciences (Emerita), Stanford University, Stanford.
Am J Psychiatry. 2016 Jul 1;173(7):672-9. doi: 10.1176/appi.ajp.2016.15101333. Epub 2016 Mar 17.
Many problems in randomized clinical trial design, execution, analysis, presentation and interpretation stem in part from an inadequate understanding of the roles of moderators and mediators of treatment outcome. As a result, 1) the results of clinical research are slow to have an impact on clinical decision making and thus to benefit patients; 2) it is difficult for clinicians or patients to apply randomized clinical trial results comparing two treatments (treatment versus control); 3) when such trials are conducted at various sites, the results often do not replicate; 4) when the results influence clinical decision making, the results clinicians obtain do not match what researchers report; and 5) the treatment effects comparing treatment and control conditions, particularly for psychiatric treatments, often seem trivial. In this review article, the author reviews and integrates the methodological literature concerning dealing with covariates in trials to emphasize their impact on clinical decision making. The goal of trials should ultimately be to establish who should get the treatment condition rather than the control condition (moderators) and to determine how to obtain the best outcomes with whatever is the preferred treatment (mediators). The author makes recommendations to clinicians as to which trials might best be ignored and which carefully considered, and urges clinical researchers to focus on studies best designed to reduce the burden of mental illness on patients.
许多随机临床试验设计、执行、分析、呈现和解释方面的问题部分源于对治疗结果的调节因素和中介因素的作用缺乏理解。因此,1)临床研究的结果难以迅速对临床决策产生影响,从而使患者受益;2)临床医生或患者难以应用比较两种治疗方法的随机临床试验结果(治疗与对照);3)当在不同地点进行此类试验时,结果往往无法复制;4)当结果影响临床决策时,临床医生获得的结果与研究人员报告的结果不匹配;5)治疗效果比较治疗和对照条件,特别是精神科治疗,往往显得微不足道。在这篇综述文章中,作者回顾并整合了关于试验中处理协变量的方法学文献,强调了它们对临床决策的影响。试验的最终目标应该是确定谁应该接受治疗条件,而不是对照条件(调节因素),并确定如何以最佳方式获得任何首选治疗的最佳结果(中介因素)。作者向临床医生提出了哪些试验可能最好被忽略,哪些需要仔细考虑的建议,并敦促临床研究人员专注于最能设计减轻患者精神疾病负担的研究。